JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-09-03
DOI
10.1111/ejh.13859
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy
- (2021) Veronika Bachanova et al. BLOOD
- Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data
- (2019) Eunyoung Kim et al. BMC CANCER
- Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma
- (2018) Enrico Tiacci et al. BLOOD
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials
- (2017) Stephanie Sasse et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging treatments for classical myeloproliferative neoplasms
- (2016) Alessandro M. Vannucchi et al. BLOOD
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints
- (2016) S. Vardhana et al. HAEMATOLOGICA
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints
- (2016) S. Vardhana et al. HAEMATOLOGICA
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
- (2014) Y. Hao et al. CLINICAL CANCER RESEARCH
- Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation†
- (2013) C. Martínez et al. ANNALS OF ONCOLOGY
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
- (2012) Bastian von Tresckow et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
- (2012) Andreas Engert et al. LANCET
- Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
- (2011) Tania Diaz et al. PLoS One
- The Role of Autologous Transplantation in Hodgkin Lymphoma
- (2011) Bastian von Tresckow et al. Current Hematologic Malignancy Reports
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
- (2010) Andreas Engert et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now